Relationship between serum levels of growth differentiation factor 15 and suppressor of cytokine signaling 3 and the prognosis of primary liver cancer patients treated with transcatheter arterial chemoembolization
Relationship between serum levels of growth differentiation factor 15 and suppressor of cytokine signaling 3 and the prognosis of primary liver cancer patients treated with transcatheter arterial chemoembolization
Objective To investigate the relationship between serum levels of growth differentiation factor 15(GDF15)and suppressor of cytokine signaling 3(SOCS3)and the prognosis of primary liver cancer patients treated with transcatheter arterial chemoembolization(TACE).Method 89 patients with primary liver cancer who underwent TACE treatment in the First Affiliated Hospital of Hebei North University from September 2018 to May 2020 were collected as the study group.After three courses of treatment,the short-term efficacy was evaluated.The study group was divided into good prognosis group(n=54)and poor prognosis group(n=35),another 89 healthy subjects were selected as the control group.Enzyme linked immunosorbent assay was applied to detect the expression levels of serum GDF15 and SOCS3,and the differences were compared between groups.Multivariate Logistic regression was applied to analyze the influencing factors of TACE treatment prognosis in patients with primary liver cancer.Receiver operating characteristic curve(ROC curve)was used to evaluate the prognostic value of serum GDF15 and SOCS3 levels.Result Compared with the control group,the serum GDF15 level in the study group was increased,and serum SOCS3 level was decreased(all P＜0.05).Compared with the good prognosis group,serum GDF15 level was increased and serum SOCS3 level was decreased in the poor prognosis group(all P＜0.05).Serum GDF15 was an independent risk factor for the prognosis of patients with primary liver cancer treated with TACE,while serum SOCS3 was an independent protective factor(all P＜0.05).The area under the ROC curve of the combined evaluation of serum GDF15 and SOCS3 for TACE treatment prognosis in primary liver cancer patients was 0.958,which was superior to the individual detection of serum GDF15 and SOCS3(Zcombination-GDF15=2.074,Zcombination-SOCS3=2.794,P=0.038,P=0.005).Conclusion Patients with primary liver cancer who have high serum GDF15 expression level and low serum SOCS3 expression level have poor prognosis after TACE treatment.Serum GDF15 and SOCS3 are factors that affect the prognosis of TACE treatment in primary liver cancer patients,and have good evaluation value for the prognosis of patients.
维普
万方数据